Dave:
>> The key is knowing the Patent and Appeal time frame. <<
You're certainly entitled to your (oft-stated) opinion, but I don't agree at all. If the appeal comes through, sensational. However, I'm here for (1) the proprietary capacity from rebuilding around the existing patents, chemistries and the library, and (2) the potential milestone and royalty revenues. IMO, this sucker, with the cash-in-hand, is a marvelous nucleus to either acquire or build around.
KDUS lost the battle with Sibia at exactly the time when pipeline was discounted to zero and "gurus" were predicting the sector's demise. Woler has done a marvelous job, preserving upside while maintaining cash at near-zero or zero burn (I think and hope!.... disclaimer, disclaimer).
I look at this as I look at any biotech investment, and I see leverage. Any positive news on the appeal would be gravy, IMO.
Merck versus Pfizer? Yeahrightsure, I have a good line on that one.
<g> |
